Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

A new brain-imaging study has revealed how ketamine produces its fast antidepressant effects in people with treatment-resistant depression. Researchers tracked changes in a critical brain receptor ...

This framework was applied to neural recordings from animals receiving one of the three anesthetics—propofol, ketamine, and dexmedetomidine.

When patients undergo general anesthesia, doctors can choose among several drugs. Although each of these drugs acts on neurons in different ways, they all lead to the same result: a disruption of the ...

Researchers used a novel PET tracer to visualize how ketamine alters AMPA receptor distribution in the brains of patients ...

Major depressive disorder (MDD) is a major global health problem and one of the leading causes of disability. About 30% of people diagnosed with ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in ...